---
title: "Astrazeneca's global oncology business Dato-DXd and lung cancer division head Lai Minglong has decided to leave"
description: "According to reporters, Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer division, has decided to leave the company to seek external development opportunities, wit"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/244578868.md"
published_at: "2025-06-15T11:45:51.000Z"
---

# Astrazeneca's global oncology business Dato-DXd and lung cancer division head Lai Minglong has decided to leave

> According to reporters, Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer division, has decided to leave the company to seek external development opportunities, with his last working day being June 30. AstraZeneca confirmed to reporters that the news is true. Public information shows that Lai Minglong joined AstraZeneca in June 2017 as Vice President of AstraZeneca China's Cardiovascular and Metabolism Business Unit and was promoted to General Manager of AstraZeneca China in 2018

According to reporters, Lai Minglong, head of AstraZeneca's global oncology business Dato-DXd and lung cancer division, has decided to leave the company to seek external development opportunities, with his last working day being June 30. AstraZeneca confirmed to reporters that the news is true. Public information shows that Lai Minglong joined AstraZeneca in June 2017 as Vice President of AstraZeneca China's Cardiovascular and Metabolism Business Unit and was promoted to General Manager of AstraZeneca China in 2018

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Trump Strikes Again: AstraZeneca's Surprise Drug Deal Could Shake Big Pharma's Global Pricing Power | AstraZeneca has reached a drug-pricing deal with President Trump to reduce Medicaid drug prices, potentially reshaping B | [Link](https://longbridge.com/en/news/260941568.md) |
| ANALYSIS-AstraZeneca's US listing may pull other firms from London in its wake | AstraZeneca's decision to upgrade its U.S. listing while retaining its London presence may influence other UK firms to c | [Link](https://longbridge.com/en/news/259563996.md) |
| Blackstone-backed Liftoff Mobile files to withdraw US listing | Feb 17 (Reuters) - Blackstone-backed (BX.N) Liftoff Mobile has filed to withdraw its initial public offering plans in th | [Link](https://longbridge.com/en/news/276118530.md) |
| Mubadala Investment Co Pjsc Dissolves Share Stake in Salesforce, Verizon; Cuts in Disney | Mubadala Investment Co PJSC has significantly reduced its shareholding in Disney by 48.7%, now holding 35,984 shares. Th | [Link](https://longbridge.com/en/news/276145715.md) |
| Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell | Mubadala Investment Co PJSC has reported its shareholdings as of December 31, 2025. The company holds 444,978 shares in  | [Link](https://longbridge.com/en/news/276145564.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.